| Literature DB >> 26882314 |
Craig W Lindsley, Kyle A Emmitte1, Corey R Hopkins, Thomas M Bridges, Karen J Gregory2, Colleen M Niswender, P Jeffrey Conn.
Abstract
Allosteric modulation of GPCRs has initiated a new era of basic and translational discovery, filled with therapeutic promise yet fraught with caveats. Allosteric ligands stabilize unique conformations of the GPCR that afford fundamentally new receptors, capable of novel pharmacology, unprecedented subtype selectivity, and unique signal bias. This review provides a comprehensive overview of the basics of GPCR allosteric pharmacology, medicinal chemistry, drug metabolism, and validated approaches to address each of the major challenges and caveats. Then, the review narrows focus to highlight recent advances in the discovery of allosteric ligands for metabotropic glutamate receptor subtypes 1-5 and 7 (mGlu1-5,7) highlighting key concepts ("molecular switches", signal bias, heterodimers) and practical solutions to enable the development of tool compounds and clinical candidates. The review closes with a section on late-breaking new advances with allosteric ligands for other GPCRs and emerging data for endogenous allosteric modulators.Entities:
Mesh：
Substances：
Year: 2016 PMID： 26882314 PMCID： PMC4988345 DOI： 10.1021/acs.chemrev.5b00656
Source DB: PubMed Journal: Chem Rev ISSN： 0009-2665 Impact factor: 60.622